Prevalence and outcomes of frailty in older patients with cancer: A prospective study from geriatric oncology clinic.
Authors: Abhijith Rajaram Rao, Anant Ramaswamy, Sharath Kumar, Shreya Gattani, Ratan Dhekale, Jyoti Krishnamurthy, Sarika Mahajan, Anuradha Daptardar, Jayita Deodhar, Manjunath Nookala, Supriya Goud, Sucheta More, Dipti Nakti, Chetan Mudliya, Nandini Sharrel Menon, Vijay Maruti Patil, Vikram Gota, Shripad Dinanath Banavali, Kumar Prabhash, Vanita Noronha
Journal: Journal of Clinical Oncology (2022)

e24011 Background: Frail older patients present with increased symptom burden, medical complexity and reduced tolerance to medical and surgical interventions. Data regarding the prevalence of frailty and its association with outcomes, such as overall survival, is limited from India. This study aimed to establish the prevalence of frailty and its association with overall survival (OS) in older patients with cancer. Methods: This was a prospective study conducted in geriatric oncology clinic of Tata memorial hospital (Mumbai India). Patients aged 60 years and above referred to the clinic were included. Frailty was identified using the Rockwoods Clinical frailty scale, and patients with a score of five or more were diagnosed as frail. Demographic details, type of cancer, stage and multi-domains geriatric assessment was done. Cancer and Ageing Research group online toxicity tool was used to assess the chemotherapy toxicity risk. A t-test or two-sample Wilcoxon rank-sum test was used to study the association between frailty status and non-categorical variables and the Pearson chi-squared test was used to measure the association between categorical variables. The Kaplan Meier survival estimation and the Cox proportional hazard model were used to perform the survival analysis. Results: Between June 2018 to January 2022, 909 patients were evaluated and 662 patients with clinical frailty score were included. The median age was 68 (60-86) years and 107 (16%) were above the age of 75 years. The most common malignancies were lung (39%), esophagus (21%) and head and neck (10%); 53% had metastatic disease. 192 (29%) were frail, and it prevalence increased with age. Frailty status was associated with poor OS (unadjusted HR: 2.512; 95% CI: 1.931-3.268). This association was significant even after adjusting for age, gender, BMI and stage of cancer (adjusted HR: 2.104; 95% CI: 1.598-2.770). Frailty was associated with comorbidities such as diabetes (32% vs 23%, p = 0.014), chronic obstructive pulmonary disease (13% vs 7%, p = 0.045) and cardiovascular disease (19% vs 12%, p = 0.017). Among the geriatric domains, frail patients had greater incidence of polypharmacy (52% vs 33%, p &lt; 0.01), slower gait speed (53% vs 12%, p &lt; 0.01), impaired cognition (25% vs 7%, p &lt; 0.01), poor nutritional status (51% vs 17%, p &lt; 0.001), depression (29% vs 8%, p &lt; 0.01) and anxiety (14% vs 5%, p &lt; 0.01). Conclusions: The prevalence of frailty among older cancer patients is high. It is associated with poor physical, cognitive and psychological resilience and is associated with poor overall survival. Our study supports the routine assessment of frailty in older patients with cancer to guide treatment decisions. Clinical trial information: CTRI/2020/04/024675.